The long-term objective of this research program is to understand at a molecular level how class I and class II molecules, encoded by the major histocompatibility complex of mouse are recognized by T-lymphocytes. This goal requires knowledge of the fundamental structural characteristics of these two families of proteins; the determination of these molecular characteristics and their relation to biological function constitute the principle focus of this proposal. The structure of """"""""novel"""""""" class I molecules, expressed on murine UV-induced fibrosarcomas and on other cell-lines, will be investigated using high-pressure liquid chromatography tryptic peptide mapping and protein sequencing. """"""""Novel"""""""" class I molecules will also be generated using molecular genetics to create new class I genes. Oligonucleotides will be sequentially excised from a normal class I gene and replaced by synthestic oligonucleotides encoding multiple amino acid differences. The recognitiion of these new class I gene products, by monoclonal antibodies and by cytotoxic T-lymphocytes, will also be investigated, in order to gain insights into the relationship between structure and function for these class I molecules. The topography of one class II molecule will be determined by examining the reactivity of specific antibodies using a cross-blocking radioimmune assay technique. The antibodies will be generated by using, as haptens, synthetic peptide fragments of this class II molecule. This basic approach should eventually lead to an understanding at a molecular level of the role which class I and class II molecules play in the control of the immune response. This is a prerequisite for the successful manipulation of the immune response and should result in rational molecular therapies for many varied diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM036804-05
Application #
3291284
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1986-04-01
Project End
1988-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Ochoa-Garay, J; McKinney, D M; Kochounian, H H et al. (1997) The ability of peptides to induce cytotoxic T cells in vitro does not strongly correlate with their affinity for the H-2Ld molecule: implications for vaccine design and immunotherapy. Mol Immunol 34:273-81
Louie, K A; Ochoa-Garay, J; Chen, P J et al. (1996) H-2Ld-alloreactive T cell hybridomas utilize diverse V alpha and V beta T cell receptor chains. Mol Immunol 33:747-58
Frelinger, J A; McMillan, M (1996) The role of peptide specificity in MHC class I-restricted allogeneic responses. Immunol Rev 154:45-58
Killion, C C; Chen, P J; Dadgari, J M et al. (1995) Dissection of cross-reactivities using a panel of H-2Ld alloreactive T cell hybridomas. Cell Immunol 164:81-9
Benichou, G; Fedoseyeva, E; Lehmann, P V et al. (1994) Limited T cell response to donor MHC peptides during allograft rejection. Implications for selective immune therapy in transplantation. J Immunol 153:938-45
Benichou, G; Fedoseyeva, E; Olson, C A et al. (1994) Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant. Int Immunol 6:131-8
Fahnestock, M L; Dadgari, J M; McMillan, M et al. (1994) Phosphatidyl inositol-linked forms of a murine class I MHC molecule expressed on Chinese hamster ovary cells retain peptide binding capability and alloreactivity. Int Immunol 6:307-14
McKinney, D M; Chen, P; McMillan, M (1994) Single Dd amino acid substitutions in the H-2Ld molecule identify antibody epitopes. Immunogenetics 39:440-3
Hioe, C E; McKinney, D M; Frelinger, J A et al. (1994) Mutations inside but not outside the peptide binding cleft of the H-2 Ld molecule affect CTL recognition and binding of the nucleoprotein peptide from the lymphocytic choriomeningitis virus. Immunogenetics 40:222-9
Benichou, G; Takizawa, P A; Olson, C A et al. (1992) Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 175:305-8

Showing the most recent 10 out of 16 publications